Interleukin-2 (IL-2) is an interleukin, which is a type of cytokine signaling molecule forming part of the immune system. It is a 15.5–16 kDa protein [5] that regulates the activities of white blood cells (leukocytes, often lymphocytes) that are responsible for immunity.

Aug 22, 2022 · Interleukin-2 (IL-2) T cells produce IL-2. The principal targets are T cells. Its primary effects are T-cell proliferation and differentiation, increased cytokine synthesis, potentiating Fas-mediated apoptosis, and promoting regulatory T cell development.

Mar 31, 2023 · High-dose interleukin-2 (IL-2) was the first approved immunotherapy for treatment of cancer. Apart from activating effector immune cells, IL-2 also stimulates regulatory T (Treg) cells, thus potentially limiting its efficacy as cancer treatment but offering opportunities to treat autoimmune diseases.

Interleukin-2 (IL-2), a 15.5-kDa variably glycosylated globular protein, was first described as T cell growth factor (TCGF), a potent mitogen and growth regulator of T cells in vitro (1–6).

Interleukin-2 (IL-2) is one of the key cytokines with pleiotropic effects on immune system. It has been approved for the treatment of metastatic renal cell carcinoma and metastatic melanoma. Recent progress has been made in our understanding of IL-2 ...

Interleukin 2 (IL-2) was one of the first cytokines to be discovered. However, the complex role of IL-2 and its receptor in the regulation of immune responses is only now emerging. This review explores the various signals triggered by IL-2 and discusses their …

Nov 7, 2004 · Here we present a broad overview of IL-2 history, functional activities, biological sources, regulation and applications to disease treatment. IL-2 exerts a wide spectrum of effects on the immune system, and it plays crucial roles in …

These factors, which include interleukin 2 (IL2), are secreted by lectin- or antigen-stimulated T cells, and have various physiological effects. IL2 is a lymphokine that induces the proliferation of responsive T cells.

IL-2 (aldesleukin, Proleukin) is now approved by the US Food and Drug Administration and by regulatory authorities in Canada and the European Community for the treatment of patients with metastatic renal cell carcinoma and melanoma.

Aug 17, 2023 · Interleukin-2 is a biologic response modifier and immune therapy used in the treatment of metastatic renal cell carcinoma and metastatic melanoma.